Detalhe da pesquisa
1.
Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade.
Nat Immunol
; 20(3): 326-336, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30778252
2.
Author Correction: Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade.
Nat Immunol
; 20(11): 1556, 2019 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-31582823
3.
Going viral: HBV-specific CD8+ tissue-resident memory T cells propagate anti-tumor immunity.
Immunity
; 54(8): 1630-1632, 2021 08 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34380061
4.
Epigenetic silencing by SETDB1 suppresses tumour intrinsic immunogenicity.
Nature
; 595(7866): 309-314, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33953401
5.
Causal identification of single-cell experimental perturbation effects with CINEMA-OT.
Nat Methods
; 20(11): 1769-1779, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37919419
6.
Loss of ADAR1 in tumours overcomes resistance to immune checkpoint blockade.
Nature
; 565(7737): 43-48, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30559380
7.
Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphoma.
Blood
; 137(10): 1353-1364, 2021 03 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32871584
8.
Immunotherapy utilization in stage IIIA melanoma: less may be more.
Front Oncol
; 14: 1336441, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38380358
9.
Subsets of IFN Signaling Predict Response to Immune Checkpoint Blockade in Patients with Melanoma.
Clin Cancer Res
; 29(15): 2908-2918, 2023 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37233452
10.
PI3K activation allows immune evasion by promoting an inhibitory myeloid tumor microenvironment.
J Immunother Cancer
; 10(3)2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35264433
11.
Reprogramming of the esophageal squamous carcinoma epigenome by SOX2 promotes ADAR1 dependence.
Nat Genet
; 53(6): 881-894, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33972779
12.
Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer.
J Clin Oncol
; 37(30): 2786-2794, 2019 10 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-31461377